Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Diefenbach, C. S., Jegede, O., Ansell, S. M., Steidl, C., Natkunam, Y., Scott, D. W., Mehta-Shah, N., Amengual, J. E., Forlenza, C. J., Cole, P. D., Bartlett, N. L., David, K. A., Advani, R. H., Ambinder, R. F., Thomas, S., Ibrahimi, S., & Kahl, B. S. (2023). Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412). Blood, 142(Supplement 1), 607–607. https://doi.org/10.1182/blood-2023-184531
Authors:
Catherine Diefenbach
Opeyemi A. Jegede
Stephen M. Ansell
Christian Steidl
Yasodha Natkunam
David W. Scott
Neha Mehta‐Shah
Jennifer E. Amengual
Christopher J. Forlenza
Peter D. Cole
Nancy L. Bartlett
Kevin A. David
Ranjana H. Advani
Richard F. Ambinder
Sachdev Thomas
Sami Ibrahimi
Brad S. Kahl
Affiliated Authors:
Jennifer E. Amengual
Columbia Affiliation:
Subjects:
Lymphoid Neoplasms (OpenAlex Topic)
Therapeutic Antibodies: Development, Engineering, and Applications (OpenAlex Topic)
Sarcoma Research and Treatment (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2023-184531
DOI:
10.1182/blood-2023-184531
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: